Davita DVA
- Market cap
- $11.7B
- PE
- 15.0×
- 10y median 16.1×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.8×
- EV/EBIT
- 10.4×
- Revenue, 12 months
- $14B
- +6% on a year ago
- Net margin
- 6.0%
- Free cash flow yield
- 13.7%
Davita trades at 15.0× trailing earnings, near its ten-year median. Revenue was $14B over the last twelve months, up 6% on a year earlier with a 6% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.1B+6% | $3.1B+8% | $3.1B+7% | $3.2B+6% | $3.3B+5% | $3.3B+5% | $3.2B+5% | $3.4B+6% | $3.4B+5% | $3.6B+10% | $3.4B+6% | $3.6B+5% | |
| SG&A | $376.9M+3% | $401.5M+6% | $362.5M+9% | $367.8M+1% | $393.5M+4% | $414.5M+3% | $374.1M+3% | $412.8M+12% | $414.4M+5% | $472.4M+14% | $421.9M+13% | $423.5M+3% |
| $495.9M+59% | $389.9M+52% | $483.8M+55% | $506.4M+25% | $534.9M+8% | $565.4M+45% | $438.9M−9% | $537.8M+6% | $505.8M−5% | $561.1M−1% | $481.9M+10% | $579M+8% | |
| Interest expense | $98.1M−2% | $96.2M−5% | $99.4M−1% | $97.7M−6% | $134.6M+37% | $138.7M+44% | $135.1M+36% | $146.1M+49% | $150.6M+12% | $148.3M+7% | $145.1M+8% | $150.3M+3% |
| Pre-tax income | $378.2M+83% | $289.1M+96% | $371.8M+73% | $371.4M+26% | $373.4M−1% | $413.7M+43% | $286.3M−23% | $368.9M−1% | $308.8M−17% | $382.8M−8% | $341.2M+19% | $435M+18% |
| $68.8M+62% | $58.5M+70% | $65.8M+50% | $71.7M+47% | $77.7M+13% | $64.5M+10% | $54.1M−18% | $93.7M+31% | $68.6M−12% | $76.7M+19% | $66.2M+22% | $91.8M−2% | |
| Net income | $246.6M+134% | $150.7M+121% | $239.6M+107% | $222.7M+25% | $214.7M−13% | $259.3M+72% | $162.9M−32% | $199.3M−11% | $150.3M−30% | $234.2M−10% | $197.5M+21% | $265.4M+33% |
| $2.62+132% | $1.62+119% | $2.65+112% | $2.50+31% | $2.50−5% | $3.09+91% | $2.00−25% | $2.58+3% | $2.04−18% | $3.29+7% | $2.87+44% | $4.02+56% | |
| 94M+1% | 92.8M+1% | 90.5M−2% | 89M−5% | 85.8M−9% | 83.9M−10% | 81.3M−10% | 77.4M−13% | 73.8M−14% | 71.3M−15% | 68.9M−15% | 66.1M−15% |
EPS, diluted: 7 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY08 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY15 and Q4 FY18: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Davita's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| DVADavita | $11.7B | 15.0× | 16.1× | n/m | 0.8× | +6% | 6.0% |
| BTSGBrightSpring Health Services | $11.9B | 36.4× | 57.7× | n/m | 0.8× | +26% | 2.5% |
| EHCEncompass Health | $12.2B | 20.2× | 18.4× | n/m | 2.0× | +9% | 10.0% |
| UHSUniversal Health Services | $11B | 7.6× | 13.6× | n/m | 0.6× | +10% | 8.4% |
| ENSGEnsign | $10.2B | 27.5× | 25.5× | n/m | 1.9× | +19% | 6.9% |
| PACSPACS | $7.5B | 27.2× | 27.2× | n/m | 1.4× | +15% | 4.8% |
| CHEChemed | $6.7B | 25.8× | 29.0× | n/m | 2.6× | +3% | 10.6% |
| THCTenet Healthcare | $21.6B | 10.4× | 11.2× | 12.9× | 1.0× | +5% | 10.3% |
| SHCSotera Health | $5.2B | 31.8× | 55.4× | n/m | 4.2× | +8% | 13.4% |
| CONConcentra Group Holdings Parent | $5B | 25.5× | 17.5× | n/m | 2.2× | +14% | 8.7% |
| LFSTLifeStance Health | $4.9B | 99.5× | 142× | n/m | 3.1× | +20% | 3.2% |
| Peer median | $8.9B | 26.5× | 26.3× | 12.9× | 1.9× | +12% | 8.6% |
Investors who own it
Investors we follow who held Davita at the end of Jun 30, 2026, from their 13F filings.
- Warren BuffettBerkshire Hathaway2.1% of portfoliotrimmed
More on Davita
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 32Hospital and care facility stocks with the highest free cash flow yield
- #7of 31Hospital and care facility stocks with the lowest EV/EBIT
- #7of 25Hospital and care facility stocks with the lowest PE ratio
- #5of 11Hospital and care facility stocks cheapest against their own PE history
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .